XBiotech (XBIT) chair John Simard discloses 17.7% ownership stake

Rhea-AI Filing Summary

XBiotech Inc. insider ownership disclosure: Chairman of the Board John Simard reports beneficial ownership of 5,719,775 common shares of XBiotech Inc. as of December 31, 2025, representing 17.7% of the company’s common shares. This includes 3,823,166 shares held directly and 1,896,609 additional shares issuable upon exercise of stock options that are immediately exercisable within 60 days of December 31, 2025.

The 17.7% figure is based on 30,487,731 XBiotech common shares outstanding as of December 31, 2025, plus the 1,896,609 option shares attributed to Simard. He reports sole voting and dispositive power over all 5,719,775 shares, with no shared voting or dispositive authority and no group arrangements disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/23/2026 - 02:06 PM Learn about SEC filing dates

FAQ

What ownership stake in XBiotech Inc. (XBIT) does John Simard report?

John Simard reports beneficial ownership of 5,719,775 XBiotech Inc. common shares, representing 17.7% of the company’s common shares as of December 31, 2025.

How is John Simard’s 5,719,775-share beneficial ownership in XBiotech (XBIT) composed?

The reported 5,719,775 shares include 3,823,166 common shares held directly and 1,896,609 common shares issuable upon exercise of stock options that are immediately exercisable within 60 days of December 31, 2025.

What percentage of XBiotech Inc. (XBIT) does 5,719,775 shares represent?

The 5,719,775 shares beneficially owned by John Simard represent 17.7% of XBiotech Inc.’s common shares, calculated using 30,487,731 shares outstanding as of December 31, 2025 plus his 1,896,609 option shares.

Does John Simard have sole or shared voting power over his XBiotech (XBIT) shares?

He reports sole voting power and sole dispositive power over all 5,719,775 shares, with no shared voting or shared dispositive power disclosed.

Is John Simard’s XBiotech (XBIT) ownership held on behalf of a group or other persons?

The filing indicates no membership in a group and notes that ownership on behalf of another person and group-related items are Not Applicable, meaning no such arrangements are reported.

What is the share count baseline used in calculating John Simard’s XBiotech (XBIT) ownership percentage?

The 17.7% ownership is based on 30,487,731 XBiotech common shares outstanding as of December 31, 2025, plus 1,896,609 shares issuable upon exercise of John Simard’s stock options.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 9)

XBIOTECH INC.

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

98400H102

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 98400H102

1

Names of Reporting Persons

John Simard

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,719,775.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,719,775.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,719,775.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

17.7 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (1) This amount includes (i) 3,823,166 shares of common stock held by the Reporting Person, (ii) 1,896,609 shares of common stock issuable upon the exercise of stock options that are immediately exercisable within 60 days of December 31, 2025 held by the Reporting Person. (2) The percentage is calculated based upon a denominator that includes (i) 30,487,731 shares outstanding as of December 31, 2025 and (ii) 1,896,609 shares that are issuable upon the exercise of stock options by the Reporting Person.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: XBIOTECH INC.
(b)	Address of issuer's principal executive offices: 5217 Winnebago Ln, Austin, TX 78744
Item 2.
(a)	Name of person filing: John Simard
(b)	Address or principal business office or, if none, residence: C/O XBiotech Inc., 5217 Winnebago Ln, Austin, TX 78744
(c)	Citizenship: Canada
(d)	Title of class of securities: Common Shares, no par value
(e)	CUSIP No.: 98400H102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,719,775 shares
(b)	Percent of class: 17.7%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5,719,775 shares
	(ii) Shared power to vote or to direct the vote: Not Applicable
	(iii) Sole power to dispose or to direct the disposition of: 5,719,775 shares
	(iv) Shared power to dispose or to direct the disposition of: Not Applicable
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

John Simard

Signature:	/s/ John Simard
Name/Title:	John Simard/Chairman of the Board of Directors, XBiotech Inc.
Date:	01/23/2026